Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
Zhejiang Provincial Key Laboratory of Pancreatic Disease, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China.
Mil Med Res. 2022 Jul 12;9(1):40. doi: 10.1186/s40779-022-00399-8.
Cholangiocarcinoma (CHOL) is one of the most aggressive tumors worldwide and cannot be effectively treated by conventional and novel treatments, including immune checkpoint blockade therapy. The mRNA vaccine-based immunotherapeutic strategy has attracted much attention for various diseases, however, its application in CHOL is limited due to the thoughtlessness in the integration of vaccine design and patient selection. A recent study established an integrated path for identifying potent CHOL antigens for mRNA vaccine development and a precise stratification for identifying CHOL patients who can benefit from the mRNA vaccines. In spite of a promising prospect, further investigations should identify immunogenic antigens and onco-immunological characteristics of CHOL to guide the clinical application of CHOL mRNA vaccines in the future.
胆管癌 (CHOL) 是全球最具侵袭性的肿瘤之一，常规和新型治疗方法（包括免疫检查点阻断疗法）均无法有效治疗。基于 mRNA 疫苗的免疫治疗策略因其在疫苗设计和患者选择方面的综合考虑，已引起了人们对各种疾病的关注，但由于其在 CHOL 中的应用缺乏深思熟虑，因此受到了限制。最近的一项研究建立了一种综合途径，用于鉴定用于 mRNA 疫苗开发的强效 CHOL 抗原和用于鉴定可从 mRNA 疫苗中获益的 CHOL 患者的精确分层。尽管前景广阔，但仍需进一步研究以确定 CHOL 的免疫原性抗原和肿瘤免疫学特征，以指导 CHOL mRNA 疫苗在未来的临床应用。
